文献速递乳腺癌

帕妥珠单抗曲妥珠单抗固定剂量皮下制剂联合化疗治疗HER2阳性早期乳腺癌的3期非劣效研究

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
PubMed 文献 · Lancet Oncol · 2020-12-21

FeDeriCa研究是一项随机、开放、国际多中心3期非劣效试验,在HER2阳性早期乳腺癌新辅助-辅助治疗中比较帕妥珠单抗+曲妥珠单抗固定剂量皮下制剂与静脉制剂联合化疗。两组总病理完全缓解率相当,安全性相似,支持FDA批准。

要点

  • 皮下固定剂量组合的第7周期帕妥珠单抗谷浓度非劣于静脉给药。
  • 两组总病理完全缓解率相当,安全性特征相似。
  • 常见3-4级不良事件为中性粒细胞减少、发热性中性粒细胞减少和腹泻。

核心结论

  • 皮下固定剂量组合提供非劣效的第7周期帕妥珠单抗血清谷浓度,总病理完全缓解率与静脉给药相当。

研究设计与样本

  • 随机、开放、国际多中心3期非劣效研究,纳入HER2阳性II-IIIC期可手术、局部晚期或炎性乳腺癌患者,按1:1随机接受静脉帕妥珠单抗+曲妥珠单抗或固定剂量皮下组合,均联合新辅助化疗。

主要发现

  • 新辅助治疗期间常见3-4级不良事件:中性粒细胞减少静脉组34例(13%)vs皮下组35例(14%),中性粒细胞计数降低31例(12%)vs27例(11%),发热性中性粒细胞减少14例(6%)vs16例(6%),腹泻12例(5%)vs17例(7%),白细胞计数降低18例(7%)vs9例(4%)。
  • 治疗相关严重不良事件:静脉组25例(10%),皮下组26例(10%)。
  • 每组各1例不良事件导致死亡(静脉组尿源性脓毒症,皮下组急性心肌梗死),均与HER2靶向治疗无关。

关键数值与推荐

  • 给药方案:静脉帕妥珠单抗840mg负荷后420mg维持,静脉曲妥珠单抗8mg/kg负荷后6mg/kg维持;皮下固定剂量组合帕妥珠单抗1200mg+曲妥珠单抗600mg负荷(15mL),后续帕妥珠单抗600mg+曲妥珠单抗600mg维持(10mL),每3周一次。
  • HER2靶向治疗共18周期,新辅助阶段与紫杉类同步4周期,术后继续14周期。

临床怎么用

  • 皮下固定剂量组合可作为HER2阳性早期乳腺癌新辅助-辅助治疗中静脉帕妥珠单抗+曲妥珠单抗的替代给药方式。
  • 给药便利性提高,无需静脉负荷剂量,安全性与其他帕妥珠单抗、曲妥珠单抗联合化疗试验一致。

局限性

  • 随访仍在进行中,长期疗效和长期安全性数据尚未成熟。
  • 开放标签设计可能影响部分主观终点评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab, trastuzumab, and hyaluronidase-zzxf) was approved by the US Food and Drug Administration (FDA) on June 29, 2020. We report the primary analysis of the FeDeriCa study, which was designed to assess the pharmacokinetics, efficacy, and safety of the fixed-dose subcutaneous formulation compared to intravenous pertuzumab plus trastuzumab in patients with HER2-positive early breast cancer in the neoadjuvant-adjuvant setting. METHODS: FeDeriCa, a randomised, open-label, international, multicentre, non-inferiority, phase 3 study, was done across 106 sites in 19 countries. Patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1, HER2-positive, operable, locally advanced, or inflammatory stage II-IIIC breast cancer, and a left ventricular ejection fraction of 55% or more were randomly assigned (1:1), using a voice-based or web-based response system, to receive intravenous pertuzumab (840 mg loading dose, followed by 420 mg maintenance doses) plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg maintenance doses) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks with neoadjuvant chemotherapy. Patients were stratified by hormone receptor status, clinical stage, and chemotherapy regimen. The investigator selected one of the two protocol-approved standard chemotherapy regimens before randomisation. Four cycles of HER2-targeted therapy were administered concurrently with the taxane. After surgery, patients continued the HER2-targeted therapy to receive an additional 14 cycles (total of 18). The primary endpoint was non-inferiority of the cycle 7 pertuzumab serum trough concentration (Ctrough; ie, cycle 8 predose pertuzumab concentration) within the fixed-dose combination for subcutaneous injection versus intravenous pertuzumab plus trastuzumab in the per-protocol pharmacokinetic population (all enrolled patients who adhered to prespecified criteria for pharmacokinetic assessment). Non-inferiority was concluded if the lower bound of the 90% CI of the geometric mean ratio was 0·8 or higher. The safety population included all patients who received at least one dose of study medication, including chemotherapy or HER2-targeted therapy. Enrolment, neoadjuvant therapy, and surgery have been completed; adjuvant treatment and follow-up are ongoing. The trial is registered with ClinicalTrials.gov, NCT03493854. FINDINGS: Between June 14, 2018, and Dec 24, 2018, 252 patients were randomly assigned to the intravenous infusion group and 248 to the fixed-dose combination group. The geometric mean ratio of pertuzumab serum Ctrough subcutaneous to serum Ctrough intravenous was 1·22 (90% CI 1·14-1·31). The most common grade 3-4 adverse events occurring during neoadjuvant treatment with HER2-targeted therapy plus chemotherapy in 5% or more of patients were neutropenia (34 [13%] of 252 patients in the intravenous infusion group vs 35 [14%] of 248 patients in the fixed-dose combination group), decreased neutrophil count (31 [12%] vs 27 [11%]), febrile neutropenia (14 [6%] vs 16 [6%]), diarrhoea (12 [5%] vs 17 [7%]), and decreased white blood cell count (18 [7%] vs nine [4%]). At least one treatment-related serious adverse event was reported in 25 (10%) patients in the intravenous infusion group and 26 (10%) patients in the fixed-dose combination group. One patient in each treatment group had an adverse event that led to death (urosepsis in the intravenous infusion group and acute myocardial infarction in the fixed-dose combination group); neither death was related to HER2-targeted therapy. INTERPRETATION: The study met its primary endpoint: the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection provides non-inferior cycle 7 pertuzumab serum Ctrough concentrations to intravenous pertuzumab plus trastuzumab in the neoadjuvant setting with comparable total pathological complete response rates, supporting the FDA approval. Safety was similar between treatment groups, and in line with other pertuzumab, trastuzumab, and chemotherapy trials. Follow-up is ongoing for long-term outcomes, including efficacy and long-term safety. FUNDING: F Hoffmann-La Roche and Genentech.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tan AR, Im SA, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2020. PMID: 33357420. doi:10.1016/S1470-2045(20)30536-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。